A Pilot Study Of Pd 0332991 In Patients With Previously Treated Mantle Cell Lymphoma

Trial Profile

A Pilot Study Of Pd 0332991 In Patients With Previously Treated Mantle Cell Lymphoma

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Apr 2017

At a glance

  • Drugs Palbociclib (Primary)
  • Indications Mantle-cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 18 Apr 2017 Results of pooled analysis (n=185) for development of semimechanistic population PK/PD model for understanding neutropenia associated with palbociclib using patient data from NCT00141297, NCT00420056, NCT00721409 trials, published in the Journal of Clinical Pharmacology
    • 12 Sep 2012 Planned End Date changed from 1 Aug 2012 to 1 Aug 2013 according to Clinicaltrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top